Dr. Sue Ettinger, DVM, DACVIM (Oncology) aka "Dr Sue Cancer Vet" will present "Utilizing the Nu.Q® Vet Cancer Test in Practice" on Monday, January 19 at 2.45pm EST. Dr. Tom Butera, Chief Executive Officer, Volition Veterinary Diagnostics Development LLC commented: "We are excited to attend VMX 2026 and are delighted that Dr Sue Ettinger will be sharing her extensive experience with our Nu.Q® Vet Cancer Test. By incorporating the Nu.Q® Canine Cancer Test into annual checkups or regular senior wellness exams, ...

Financial Performance & Growth - Veracyte achieved approximately $516 million in total revenue for 2025, with a 17% testing revenue growth[12] - The company expects to achieve greater than 25% adjusted EBITDA in 2025[14] - Veracyte anticipates revenue between $570 million and $582 million in 2026, representing a 10-13% year-over-year growth[61] - The company projects a 14-16% year-over-year testing growth in 2026[61] - The company anticipates approximately 25% adjusted EBITDA margin in 2026[61] Product & Market Expansion - Over 800,000 patients have been served with Veracyte's tests to date[12] - Decipher Prostate has achieved approximately 33% market penetration in the U S[19] - Afirma has achieved approximately 38% market penetration in the U S thyroid cancer market[31] - The company plans to launch TrueMRD for muscle-invasive bladder cancer (MIBC) and Prosigna LDT in 2026[64] - Veracyte is developing IVD versions of its tests, including Decipher qPCR and Prosigna NGS, for geographic expansion[54]

Core Insights - Mainz Biomed N.V. is set to present its blood-based mRNA signature for pancreatic ductal adenocarcinoma (PDAC) detection and differentiation from intraductal papillary mucinous neoplasms (IPMN) at the AACR 2026 Annual Meeting in San Diego from April 17 to 22, 2026 [1][3] - The company will showcase results from a verification study involving a proprietary combination of blood-derived mRNA biomarkers and AI-assisted modeling, tested on a cohort of 30 subjects [2] - The aim of this study is to revolutionize pancreatic cancer screening practices and contribute to reducing cancer mortality rates globally [3] Company Overview - Mainz Biomed specializes in developing molecular genetic diagnostic solutions for life-threatening conditions, with its flagship product being ColoAlert, a non-invasive early-detection test for colorectal cancer marketed in Europe [4] - The company is currently conducting the eAArly DETECT 2 clinical study in preparation for a pivotal FDA study for regulatory approval in the U.S. [4] - Additionally, Mainz Biomed is developing PancAlert, an early-stage pancreatic cancer screening test utilizing real-time PCR multiplex detection of molecular-genetic biomarkers in blood and stool samples [4]

Core Insights - BGI Genomics and Roche Diagnostics have launched Alzheimer's disease tests in China to enhance access to user-friendly diagnostic and monitoring options for patients [1] Company Developments - BGI Genomics and Roche Diagnostics are collaborating to provide new testing solutions for Alzheimer's disease in the Chinese market [1] Industry Trends - The introduction of these tests reflects a growing trend in the healthcare industry towards improving diagnostic capabilities and patient monitoring for neurodegenerative diseases [1]

Core Insights - 2025 was a significant year for LabCorp, focusing on four core therapeutic areas: oncology, women's health, autoimmune, and neurology [2] - The company launched over 100 tests in 2025, with the majority targeting the identified therapeutic areas, which are expected to grow 2 to 3 times faster than the overall diagnostic market [2] Strategic Focus - LabCorp's strategic focus on specific therapeutic areas is aimed at capitalizing on growth opportunities within the diagnostic market [2] - The anticipated growth rate of 2 to 3 times faster than the rest of the market indicates a strong potential for revenue increase in these segments [2]

NeoGenomics (Nasdaq: NEO) JP Morgan Healthcare Conference Investor Presentation January 2026 Mission We save lives by improving patient care. Vision We are becoming the world's leading provider of comprehensive cancer testing, data and solutions through uncompromising quality, exceptional customer experience, and innovative products and services. Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company"). Statements contained herein ar ...

Danaher (NYSE:DHR) FY Conference January 13, 2026 02:15 PM ET Company ParticipantsCasey Woodring - VP and Equity ResearchRainer Blair - CEOCasey WoodringAll right, great. Thank you, everybody, for joining me today. I'm Casey Woodring from the Life Science Tools and Diagnostics team. Welcome to our J.P. Morgan Healthcare Conference. Pleased to be joined by Danaher's CEO, Rainer Blair. Rainer's going to go through the corporate presentation for Danaher, and then we'll do a Q&A session afterwards. Rainer, all ...

Danaher Corporation Rainer Blair, President & CEO J.P. Morgan Healthcare Conference | January 13, 2026 Innovation at the speed of life. Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding Danaher's estimated or anticipated financial performance and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward looking" statements within the meaning of the federal secu ...

Core Insights - The American Journal of Transplantation position paper emphasizes the importance of decentralized organ health testing, particularly highlighting the role of absolute quantification of donor-derived cell-free DNA (dd-cfDNA) as a diagnostic marker, which aligns with iMDx's GraftAssure family of assays [1][2] Industry Context - The STAR working group, a collaboration between the American Society of Transplantation and the American Society for Histocompatibility and Immunogenetics, advocates for high-quality, standardized decentralized dd-cfDNA testing to support multicenter studies and improve patient management [2][3] - The publication indicates a significant demand for decentralized testing solutions in the transplant community, which is seen as a positive indicator for iMDx's business strategy [2][3] Company Strategy - iMDx aims to provide industry-leading molecular diagnostic test kits that decentralize access to organ health testing for kidney transplant patients, targeting a market exceeding $1 billion for transplant rejection testing [3][4] - The company is focused on developing a high-quality assay with transparent quality control to enhance access to dd-cfDNA testing, which is viewed as a promising biomarker for transplant rejection [3][4] Product Overview - iMDx's GraftAssure product line includes: - GraftAssureCore: A laboratory-developed test currently reimbursed by CMS and performed at iMDx's CLIA-certified lab [6] - GraftAssureIQ: A research-use-only kit for non-clinical applications [6] - GraftAssureDx: An in vitro diagnostic kit under development for clinical decision-making [6]

American Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as a diagnostic marker, a key feature of iMDx’s flagship GraftAssureTM family of assays NASHVILLE, Tenn., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today congratulated the STAR working group on its position paper in the American Journal of Transplantation in recognizing the need for decentralized organ health testing in the global transplant comm ...